Drug and Medication Industry: Wakayama Medical University – Developmental Therapeutics Review – Q4 2010

• Publication date: December 2010

The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by G...

The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- Wakayama Medical University - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Wakayama Medical University human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Wakayama Medical University with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Wakayama Medical University’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Wakayama Medical University’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Wakayama Medical University in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Wakayama Medical University’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Wakayama Medical University.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Wakayama Medical University and identify potential opportunities in those areas.

Global Therapy Industry

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Wakayama Medical University Snapshot 5
Key Information 5
Key Facts 5
Wakayama Medical University – Research and Development Overview 6
Key Therapeutic Areas 6
Wakayama Medical University – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Pipeline Products – Combination Treatment Modalities 10
Wakayama Medical University – Pipeline Products Glance 11
Wakayama Medical University Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Wakayama Medical University – Drug Profiles 13
Capecitabine + Radiation Therapy 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
docetaxel + Cisplatin + 5-FU 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Docetaxel + Cisplatin + Fluorouracil 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
S-1 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Tegafur/Uracil + Peg Interferon 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
URLC10-177 + TTK-567 + CpG7909 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Gemcitabine + VEGFR2-169 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
S1 + Radiotherapy 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
VEGFR2-169 + Gemcitabine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Wakayama Medical University – Pipeline Analysis 25
Wakayama Medical University – Pipeline Products by Therapeutic Class 25
Wakayama Medical University Pipeline Products By Target 27
Wakayama Medical University – Pipeline Products by Route of Administration 29
Wakayama Medical University – Pipeline Products by Molecule Type 30
Wakayama Medical University – Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 33
Contact Us 33
Disclaimer 33List of Tables
Wakayama Medical University – Pipeline by Therapy Area and Indication, 2010 7
Wakayama Medical University – Pipeline by Stage of Development, 2010 8
Wakayama Medical University – Monotherapy Products in Pipeline, 2010 9
Wakayama Medical University – Combination Treatment Modalities in Pipeline, 2010 10
Wakayama Medical University - Phase II, 2010 11
Wakayama Medical University - Phase I, 2010 12
Wakayama Medical University - Pipeline By Therapeutic Class, 2010 26
Wakayama Medical University - Pipeline By Target, 2010 28
Wakayama Medical University – Pipeline By Route of Administration, 2010 29
Wakayama Medical University – Pipeline By Molecule Type, 2010 30

List of Figures
Wakayama Medical University – Pipeline by Therapy Area and Indication, 2010 7
Wakayama Medical University – Pipeline by Stage of Development, 2010 8
Wakayama Medical University – Monotherapy Products in Pipeline, 2010 9
Wakayama Medical University – Combination Treatment Modalities in Pipeline, 2010 10
Wakayama Medical University – Pipeline By Therapeutic Class, 2010 25
Wakayama Medical University - Pipeline By Target, 2010 27
Wakayama Medical University – Pipeline By Route of Administration, 2010 29
Wakayama Medical University – Pipeline By Molecule Type, 2010 30